EUREKA Italy - Evaluation of Real-life Use of KLOX BioPhotonic System in Chronic Wounds Management
EUREKA Italy - The Evaluation of Real-life Use of KLOX BioPhotonic System in Chronic Wounds Management: a Reproducibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated written informed consent form;
- Adult patient (at least 18 years old) having received a diagnosis of venous leg ulcer, diabetic foot ulcer or pressure ulcer by the Investigator;
- The treating physician (investigator) believes the KLOX LumiHeal BioPhotonic System would be an appropriate option;
- Both male and female patients must be willing to adhere to a medically-accepted birth control method during the course of the study;
- Willingness to comply with study requirements (visits, treatments, etc.).
Exclusion Criteria:
- Female pregnant patient (by medical history or as ascertained by a pregnancy test);
- Breast-feeding female patient;
- Patients taking drugs/products (e.g., methotrexate, chemotherapy agents) or with conditions (e.g., porphyria) known to induce severe photosensitivity reactions;
- Patients with known skin hypersensitivity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: LumiHeal
Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
|
Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events, Serious Adverse Events and Device Incidents
Time Frame: Up to 34 weeks
|
Number of patients with adverse events, serious adverse events and device incidents.
|
Up to 34 weeks
|
|
Rate of complete wound closure
Time Frame: Up to 34 weeks
|
Up to 34 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound area reduction over time
Time Frame: Up to 34 weeks
|
Up to 34 weeks
|
|
|
Time to complete wound closure
Time Frame: Up to 34 weeks
|
Up to 34 weeks
|
|
|
Incidence of wound breakdown, following wound closure
Time Frame: Up to 34 weeks
|
Up to 34 weeks
|
|
|
Ease of use by healthcare professionals (questionnaire)
Time Frame: Up to 34 weeks
|
To collect feedback on the ease of use of the KLOX LumiHeal BioPhotonic System in the management of chronic wounds, from health care professional users.
|
Up to 34 weeks
|
|
Impact of treatment on Health-related Quality of Life (CWIS questionnaire)
Time Frame: Up to 34 weeks
|
To collect quality of life data in patients treated with the KLOX LumiHeal BioPhotonic System.
|
Up to 34 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ORS-K1002-P001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.